Overview

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

Status:
Active, not recruiting

Trial end date:
2022-02-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Antibodies